Wegovy 0.5 mg: the first real step up in your dosing schedule

What the licensed titration schedule says about 0.5 mg

The Wegovy dosing pathway is not arbitrary. It was developed from clinical trial data and is reflected in the approved Summary of Product Characteristics, which you can review in full on the Electronic Medicines Compendium. The sequence runs: 0.25 mg for four weeks, then 0.5 mg for four weeks, then 1.0 mg, 1.7 mg, and finally 2.4 mg as the maintenance dose. Each rung exists to reduce the likelihood of nausea, vomiting and other gastrointestinal effects that can accompany GLP-1 receptor agonists when introduced too quickly.

At 0.5 mg, semaglutide is present in meaningful concentrations but not yet at the levels that produced the headline weight-loss results seen in the STEP 1 trial. That 68-week study, published in the New England Journal of Medicine, reported an average body-weight reduction of around 15% at the 2.4 mg maintenance dose. The 0.5 mg phase is part of getting there safely, not a destination in itself. Skipping or shortening dose steps is a clinical decision, not a patient one, and is assessed individually by the prescriber.

For more on how each step compares, the full breakdown of Wegovy's dose schedule sets out the reasoning behind each stage.

Side effects at the 0.5 mg stage: what the data shows

Gastrointestinal effects are the most commonly reported reactions across the semaglutide programme. Nausea, loose stools, constipation, bloating and reflux appear in the clinical trial data and in the NHS's own patient information. The NHS semaglutide medicines page lists these clearly and is worth reading before you start treatment.

For most people these effects are mild to moderate and settle within a week or two of starting a new dose. The 0.5 mg step sometimes catches people off guard if the 0.25 mg starter caused very little: a slightly sharper GI response at 0.5 mg is normal and does not mean you cannot tolerate the medicine. Staying well hydrated and eating smaller, lower-fat meals during the adjustment window helps considerably.

Serious but less common reactions to be aware of at any dose include signs of acute pancreatitis: severe, persistent stomach pain that radiates toward the back, with or without vomiting, warrants urgent medical attention. The MHRA issued a Drug Safety Update in January 2026 specifically highlighting this for GLP-1 medicines. If you experience this, seek help promptly rather than waiting for your next clinical review. You can also report suspected side effects through the MHRA Yellow Card scheme.

What 0.5 mg does not tell you about your results

A common concern among people starting Wegovy is that early progress at low doses predicts final outcomes. It does not, reliably. Weight loss during the titration phase is often modest; the medicine's appetite-suppressing effect builds as doses increase and plasma concentrations stabilise. Judging the treatment by what happens at 0.5 mg is a bit like assessing a long walk by the first five minutes.

Appetite reduction, improved satiety and early changes to food preferences are often noticed before the scale moves significantly. These are signs the medicine is working as it should. If you are curious about how 0.5 mg compares to the next step, the 1.0 mg dose page covers what changes when you move up.

On the question of cost at each stage: treatment pricing varies by dose and provider, and our page on the different Wegovy mg options gives context on what private prescriptions typically include, alongside details on the 2 mg Wegovy stage for those planning ahead. Worth checking before you compare headline figures from different services.

Who prescribes 0.5 mg, and what the clinical review involves

Wegovy is a prescription-only medicine. No online service can lawfully supply it following a quick form-fill with no clinical assessment. At nume, a GPhC-registered Independent Prescriber personally reads your consultation; a real clinician looks at your answers, not an automated flag system. Orders placed by midday Monday to Friday are reviewed the same day, and treatment is dispatched once approved, arriving free the next working day via DPD in plain packaging.

Eligibility for semaglutide under its UK licence covers adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds may apply for some ethnic backgrounds under UK guidance. If you are already established on a dose from another provider, a transfer is possible; our prescribers check your treatment history before issuing a prescription at any step, including 0.5 mg. You can verify our pharmacy on the GPhC register (registration 9012878).

The clinical team, including our lead prescriber Mostafa Damghani, reviews every new and repeat order. If you have questions before starting, our FAQ page covers the practicalities. When you are ready, start your free consultation and a prescriber will take it from there.